Objective Anti-inflammatory 
INTRODUCTION
Fetal ductal constriction is a clinical condition associated with high morbidity and potential mortality. Patency of the fetal ductus arteriosus (DA) depends on the levels of circulating prostaglandins (PG), which are produced via the cyclo-oxygenase (COX) pathway during the inflammatory response 1 and are released physiologically in pregnancy especially during the third trimester 2 . COX-inhibiting substances, such as non-steroidal anti-inflammatory drugs (NSAIDs), can interfere with PG metabolism and induce constriction of the DA [3] [4] [5] [6] . To manage or prevent DA constriction, it is therefore important to reduce fetal exposure to substances that may interfere with PG biosynthesis, such as anti-inflammatory drugs and polyphenol-rich foods 1, [7] [8] [9] [10] [11] [12] [13] . Polyphenols, the most abundant antioxidants present in the diet, are distributed widely in vegetables. One of the possible mechanisms to explain their activity is inhibition of synthesis and release of inflammatory mediators 14 ; however, clinical studies investigating the effect of polyphenols on inflammatory responses are inconclusive and, in most cases, have evaluated only clinical outcomes 15, 16 . The role of polyphenols in inflammatory response, and associated modifications of the plasma concentration of prostaglandin E2 (PGE2) in pregnant women, has not yet been studied. Despite the potential benefits of a diet rich in polyphenols [9] [10] [11] [12] [13] , research has shown that a high consumption of these substances in the third trimester of pregnancy may reduce plasma levels of PGE2 and result in DA constriction [17] [18] [19] [20] , and therefore restriction of their ingestion during this period is recommended 21 . Fetal ductal constriction has high prevalence 22 and may result in severe fetal and neonatal complications 23, 24 . These considerations raised the hypothesis that reversal of fetal ductal constriction after maternal restriction of polyphenol-rich foods is accompanied by increase in PGE2 levels. Demonstration of this effect would represent an advancement in knowledge and might result in changes on dietary guidance during pregnancy and prevention of perinatal complications, with potential impact on public health.
The purpose of this study was to test the hypothesis that reversal of fetal ductal constriction in the third trimester of pregnancy after maternal restriction of polyphenol-rich foods is accompanied by an increase in plasma levels of PGE2.
METHODS

Study design and participants
This was a controlled clinical trial of women with singleton pregnancy at ≥ 28 weeks undergoing fetal echocardiography for any indication. The intervention group included cases with a diagnosis of fetal ductal constriction, as evidenced by echocardiographic findings of DA peak systolic velocity ≥ 1.40 m/s, DA maximum diastolic velocity ≥ 0.30 m/s and DA pulsatility index (determined as (peak systolic velocity − peak diastolic velocity)/mean velocity) ≤ 2.2, and with no use of drugs or pharmacological anti-inflammatory agents. The control group consisted of fetuses with normal echocardiographic diagnosis. The predictor variable was nutritional guidance and the outcome variable the modification of plasma levels of PGE2.
The study was approved by the Research Ethics Committee of the Institute of Cardiology of Rio Grande do Sul (ClinicalTrials.gov identifier: NCT03111602). All participants provided signed informed consent after being fully informed of the purpose of the study. The study was conducted according to guidelines of Resolution 466/12 of the National Council of Health for research with human beings, including anonymity and privacy of participants. A randomized clinical trial was not conducted due to the risk of maintenance of fetal ductal constriction in the intervention group, considering that the conceptual model to obtain a state of equipoise would not be met 25 .
Exclusion criteria for fetal characteristics were: cardiac malformations other than ductal constriction, or any other malformations; intrauterine growth restriction; increased nuchal translucency (> 95 th percentile); chromosomal disorders suspected on fetal echocardiography or obstetric ultrasound morphological assessment; signs of any type of hydrops fetalis, or heart arrhythmia. Maternal exclusion criteria included: hypertension, diabetes mellitus, structural or functional cardiac abnormality, current infection and positive serology for toxoplasmosis, HIV, cytomegalovirus, hepatitis C; current use of NSAIDs, steroids, antidepressants, illicit drugs, alcohol or smoking; multiple pregnancy; ongoing labor or premature rupture of membranes; unsuitable echocardiographic window; having received previous nutritional guidance in relation to restricted intake of polyphenol-rich foods; and refusal to participate in the study.
Logistics
In cases with fetal ductal constriction, the mothers received nutritional guidance to restrict consumption of polyphenol-rich foods. Women in the control group were also interviewed to assess the amount of total polyphenols (TP) in their diet, but were not advised to avoid polyphenol-rich foods. Blood samples were collected from all participants for the evaluation of inflammatory processes. All women were directed to return after 2 weeks for follow-up echocardiographic assessment, blood sample collection and nutritional evaluation.
Fetal echocardiography was performed with commercially available ultrasound equipment capable of producing high-resolution images in M-mode, two-dimensional, continuous and pulsed-wave Doppler, and color-flow mapping (GE Vivid E9, GE Healthcare Ultrasound, Milwaukee, WI, USA), and devoted exclusively to the project. Electronic transducers were used with frequencies of 1.7-5 MHz.
Echocardiographic examinations assessed, by sequential analysis, the atrial situs, heart position, systemic and pulmonary venous drainage, atrioventricular and ventricular-arterial connections, foramen ovale, aortic arch, ductal arch, and possible malformations. The DA was evaluated by color-flow Doppler in a longitudinal plane of the ductal arch or a transverse plane at the level of three vessels and trachea. The presence of flow turbulence was registered. The 2-mm pulsed-wave Doppler sample was positioned at the most distal, descending aortic end of the DA, with a maximum angle of 30
• , without angle correction; 100-200-Hz filters, 50 cm/s scanning and five spectrum curves were applied. Clear Doppler signals and uniform waveforms were recorded. Fetal heart rate was recorded. In one of the cycles, the peak-systolic, peak-diastolic and end-diastolic velocities (m/s) were determined. The DA pulsatility index was calculated automatically by the echocardiography system after manual tracing of the spectral curve, using the equation: (peak systolic velocity − peak diastolic velocity)/mean velocity.
Fetal ductal constriction was diagnosed by the following criteria: ductal peak systolic velocity ≥ 1.40 m/s, maximum ductal diastolic velocity ≥ 0.30 m/s and ductal pulsatility index ≤ 2.2. Additional parameters indicative of functional effects of ductal constriction were also evaluated, but were not essential to the diagnosis; these included ductal flow turbulence on color flow mapping, right-to-left ventricle diameter ratio ≥ 1.3, pulmonary artery to aorta diameter ratio ≥ 1.3, bulging of the interventricular septum into the left ventricle during the cardiac cycle and tricuspid valve regurgitation. Women were included in the intervention group after agreement between at least two researchers with respect to the diagnostic criteria of fetal ductal constriction.
Two weeks after the first visit, a second Doppler echocardiographic examination was performed, by an investigator blinded to the study, group allocation and results of the first examination. Normal values of transductal flow velocities and pulsatility index, as well as absence of any other associated abnormalities or complications, were considered as a favorable outcome, and were confirmed by a second examiner.
TP in maternal diet was quantified using a food frequency questionnaire (FFQ) validated for use in pregnant women 26 . Measurement of TP from the food questionnaire followed an American database 27 as well as a French database 28 . A quantification of food consumption in southern Brazil 29 was also used for these estimates. TP results after analysis of the dietary questionnaires were described in mg/day. After answering the FFQ, all pregnant women in the intervention group (with diagnosis of fetal DA constriction) were directed to restrict polyphenol-rich foods, i.e. foods with more than 30 mg of polyphenol per 100 g, according to the American database 27 , for a period of 2 weeks. After 2 weeks, participants underwent echocardiographic re-evaluation and answered again the FFQ. The amount of ingested TP during this period was calculated. On reassessment, the participants of the intervention group were guided to maintain polyphenol-rich food restriction until the end of pregnancy, and to consume alternative foods to replace the essential micronutrients present in polyphenol-rich foods.
Blood samples were collected at the first visit and at the 2-week follow-up assessment for the evaluation of plasma levels of PGE2. Blood samples were centrifuged and the plasma was aliquoted in microtubes and immediately stored at −80
• C until the time of analysis. PGE2 was quantified by capture enzyme-linked immunoabsorbent assay (eBioscience kit, Santa Clara, CA, USA; and Cusabio Biotech kit, Atlanta, GA, USA), in accordance with the manufacturers' instructions. Optical densities were measured in a spectrophotometer (Spectramax M2e, Molecular Devices, Sunnyvale, CA, USA) at 25
• C, with reduction of background. The measurements were obtained through four-parameter linear regression (Microsoft Excel) and data were expressed as pg of protein per mL (pg/mL).
Precautions were taken to control for main biases: selection bias, by following rigorously the inclusion and exclusion criteria for the selection of study participants; assessment bias, by ensuring that all measurements were performed by observers experienced in fetal echocardiography; and confounding factors, by pairing fetuses with gestational ages within the third trimester in the two groups. Only echocardiographic images of good quality were considered. Doppler angle < 30
• was used in measurements. Data were collected during periods of fetal apnea and with no movement.
Sample size calculation
No report is available in the literature investigating the inflammatory outcome evaluated in this study in pregnant women. Therefore, the sample size was calculated on the basis of the mean and SD of PGE2 levels measured in 20 samples (10 from each group) of a pilot of the present study, which was 741 ± 217 pg/mL. There was an expected difference of 20% in levels of PGE2, based on a convenience sample of 33% of the final sample of this study. A sample of 29 pregnant women in each group was required for a power of 90% and a significance level of 5%.
Statistical analysis
Results were expressed as mean ± SD or median and interquartile range (IQR) for continuous variables. Student's t-test for independent samples was used for comparison of continuous variables with normal distribution between groups. Pre-and post-treatment diagnostic parameters of fetal ductal constriction in both groups were analyzed by a t-test for paired samples. The Wilcoxon signed-rank test was used for intragroup analysis of the amount of polyphenols ingested (food questionnaire) and the change in plasma levels of PGE2 before and after the 2-week intervention. A significance level of 5% was considered statistically significant. SPSS Statistics version 19.0 (IBM Corp., Armonk, NY, USA) was used for data analysis.
RESULTS
Data were collected between May 2014 and August 2016.
Forty-one women were recruited for the control group and 37 for the intervention group, but one patient in the control group and two in the intervention group were lost due to unexpected pregnancy loss. Therefore, 40 normal pregnancies were assessed in the control group and 35 with fetal DA constriction in the intervention group. Maternal characteristics were similar between the two groups, with the exception of gestational age, which was lower in the control group, but was in all cases within the third trimester of pregnancy (Table 1) . Reported and FFQ-evaluated consumption of polyphenols and plasma levels of PGE2 observed at the two time points of the study are presented in Table 2 . Median consumption of polyphenols and plasma levels of PGE2 at initial evaluation were lower in the control group (904.30 mg/day and 584.16 pg/mL, respectively) compared with the intervention group (1234.82 mg/day and 1091.80 pg/mL, respectively), but the difference was not statistically significant.
Intragroup analysis showed a significant reduction in the consumption of polyphenols (P < 0.001) in the intervention group accompanied by increase in plasma levels of PGE2 (P < 0.05) after the 2-week intervention. No significant differences were observed in the control group for consumption of polyphenols (P = 0.455) or plasma levels of PGE2 (P = 0.150).
Echocardiographic data before and after intervention in the control and intervention groups are presented in Figure 1 . After the 2-week dietary guidance, the intervention group showed reduction of DA systolic velocity (1.34 ± 0.32 vs 1.92 ± 0.29 m/s, P < 0.001) and diastolic velocity (0.22 ± 0.06 vs 0.45 ± 0.20 m/s, P < 0.001), and increased pulsatility index (2.53 ± 0.20 vs 1.96 ± 0.17, P < 0.001), compared with measurements at first examination, reflecting reversal of fetal ductal constriction. No differences were observed in the control group for these parameters, with similar values at the first echocardiographic assessment and after 2 weeks for ductal systolic velocity (0.86 ± 0.25 vs 0.68 ± 0.47 m/s, P = 0.193), diastolic velocity (0.14 ± 0.025 vs 0.16 ± 0.024 m/s, P = 0.415) and pulsatility index (2.54 ± 0.28 vs 2.81 ± 0.23, P = 0.075). Data are presented as mean ± SD. *Comparison between groups performed using Student's t-test for independent data. BMI, body mass index at first consultation; GA, gestational age. 
Figure 1
Mean ductal peak systolic velocity (a), peak diastolic velocity (b) and pulsatility index (c) assessed at first fetal echocardiographic examination ( ) and at 2-week follow-up ( ), in women with diagnosis of fetal ductal constriction who received dietary guidance to restrict consumption of polyphenol-rich foods (intervention group) and those with normal pregnancy (controls). Table 2 Consumption of total polyphenols (TP) and level of prostaglandin E2 (PGE2) at first consultation and at 2-week follow-up assessment, in women with diagnosis of fetal ductal constriction who received dietary guidance to restrict consumption of polyphenol-rich foods (intervention group) and those with normal pregnancy (control group) 
DISCUSSION
This is the first study evaluating the possible association between maternal consumption of polyphenols in pregnancies with premature fetal ductal constriction and plasma levels of PGE2. The findings showed that, after nutritional guidance for reduction of consumption of polyphenols in the intervention group, plasma levels of PGE2 increased and fetal ductal constriction was reversed. No modifications were observed in the control group during the period of the study. These findings suggest that maternal restriction of polyphenol-rich foods in the third trimester reverses fetal ductal constriction through increase in plasma levels of PGE2. We are not aware of any other comparative investigation of reversal of fetal ductal constriction unrelated to pharmacological agents.
Several studies have demonstrated a reduction of PGE2 after polyphenol administration [30] [31] [32] [33] [34] [35] . Our results, showing increase in plasma levels of PGE2 after restriction of polyphenols in the third trimester, reinforce this knowledge. The reversal of fetal ductal constriction observed in the intervention group, associated with an increase in plasma levels of PGE2, is attributed to the maternal restriction of polyphenol-rich foods for 2 weeks, showing that this period of time is sufficient for this effect. The modification of inflammatory indicators by introduction or removal of polyphenols depends on the individual variability in absorption and excretion of nutrients, bioavailability of the substance, period of exposure or restriction to the food and the amount of polyphenols present, which varies depending on the food source 9, 10, 15, 26 . Among prostaglandins, PGE2 is the main mediator of inflammation in the cardiovascular system 13 . Studies in patients presenting inflammatory conditions show significant changes in the levels of PGE2 after dietary intervention for polyphenol consumption, as is the case in the present study in which women in the final period of gestation, considered a pro-inflammatory period, were investigated 15 . Considering the diagnostic parameters of fetal ductal constriction, the intervention group showed a decrease in DA systolic and diastolic velocity values and an increase in pulsatility index after 2 weeks of dietary guidance, with reversal of ductal constriction. No changes were observed in the control group. These results corroborate a previous study aimed at demonstrating this effect 18 . Polyphenols have a similar effect to that of NSAIDs in inhibiting COX, thus decreasing PG synthesis 11 . In a recent study, supplementation with polyphenol capsules in women of childbearing age inhibited the increase in markers of inflammation and oxidative stress 36 . Experimental studies showed that maternal consumption of polyphenols in the third gestational trimester changes the dynamics of fetal DA, which may result in ductal constriction 19 . In addition, clinical studies have shown that maternal consumption of higher amounts of polyphenol-rich foods may be associated with changes in DA dynamics 17 , and that maternal restriction of these substances can reverse ductal constriction 18 .
The main limitation of the present study is that it was not randomized. However, its controlled clinical design was defined by consideration of the existing evidence on the relationship between consumption of polyphenols and ductal constriction and the lack of information on the safe consumption of polyphenols in late gestation. This ethical decision prevented a possible worsening of fetal ductal constriction, which shows no spontaneous reversal when a polyphenol-rich diet is maintained 18 . In other words, there was no equipoise to justify randomization of this study 25 . To control for selection, assessment and confounding biases, inclusion and exclusion criteria were followed strictly in the selection of study participants, and all measurements were performed by observers with experience in fetal echocardiography. Echocardiographic images of poor quality were not considered.
In conclusion, the increased level of the inflammation marker PGE2 observed in this study is possibly related to the restricted consumption of polyphenol-rich foods following dietary intervention, and no modifications were observed in the control group that did not receive nutritional guidance. The results of dietary guidance for maternal restriction of polyphenol-rich foods at the end of pregnancy showed that the observed pro-inflammatory effect is probably associated with increase of plasma levels of PGE2, which may explain the reversal of fetal ductal constriction.
